Skip to main content

Table 1 Patient characteristics

From: Management of brain metastasis with magnetic resonance imaging and stereotactic irradiation attenuated benefits of prophylactic cranial irradiation in patients with limited-stage small cell lung cancer

  All (n = 124) PCI (n = 29) non-PCI (n = 95) P
Age, year (range) 72 (37–88) 65 (37–74) 74 (37–88) <0.0001
Male 113 (91) 27 (93) 86 (90) 0.778
Smoking status     0.721
 Current 61 (49) 15 (52) 46 (48)  
 Former 60 (48) 14 (48) 46 (48)  
 Never 2 (2) 0 2 (2)  
 Unknown 1 (1) 0 1 (1)  
Number of packets 46 (0–210) 60 (12–140) 45 (0–210) 0.226
Clinical stage     0.0009
 Stage I/II 51 (41) 5 (17) 46 (49)  
 Stage III 73 (59) 24 (83) 49 (52)  
ECOG PS     0.337
 0 70 (56) 20 (69) 50 (53)  
 1 50 (40) 8 (28) 42 (44)  
 2 4 (3) 1 (3) 3 (3)  
Initial treatment     0.094
Chemoradiotherapy 61 (49) 19 (66) 42 (44)  
 Radiotherapy 4 (3) 0 (0) 4 (4)  
 Surgery 41 (34) 8 (28) 33 (35)  
 Chemotherapy 18 (15) 2 (7) 16 (17)  
Response to initial treatment     0.0052
 Complete response 82 (66) 25 (86) 57 (60)  
 Good partial response 42 (34) 4 (14) 38 (40)  
Cranial MRI before PCI 85 (69) 28 (97) 57 (60) <0.0001
Observation period (month) 20 (6–94) 20 (6–82) 20 (6–94) 0.945
  1. Data are numbers of patients (percentage of patients) otherwise indicated
  2. PCI prophylactic cranial irradiation; ECOG PS Eastern Cooperative Oncology Group performance status